Abbott Laboratories
NYSE:ABT

Watchlist Manager
Abbott Laboratories Logo
Abbott Laboratories
NYSE:ABT
Watchlist
Price: 113.14 USD -1.61% Market Closed
Market Cap: 196.2B USD
Have any thoughts about
Abbott Laboratories?
Write Note

Abbott Laboratories
Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Abbott Laboratories
Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Abbott Laboratories
NYSE:ABT
Cash Equivalents
$7.6B
CAGR 3-Years
-7%
CAGR 5-Years
13%
CAGR 10-Years
8%
Becton Dickinson and Co
NYSE:BDX
Cash Equivalents
$1.7B
CAGR 3-Years
-9%
CAGR 5-Years
26%
CAGR 10-Years
-1%
Boston Scientific Corp
NYSE:BSX
Cash Equivalents
$2.5B
CAGR 3-Years
9%
CAGR 5-Years
55%
CAGR 10-Years
26%
Edwards Lifesciences Corp
NYSE:EW
Cash Equivalents
$3.7B
CAGR 3-Years
35%
CAGR 5-Years
25%
CAGR 10-Years
25%
Stryker Corp
NYSE:SYK
Cash Equivalents
$3.9B
CAGR 3-Years
15%
CAGR 5-Years
15%
CAGR 10-Years
11%
Intuitive Surgical Inc
NASDAQ:ISRG
Cash Equivalents
$1.8B
CAGR 3-Years
32%
CAGR 5-Years
23%
CAGR 10-Years
14%
No Stocks Found

Abbott Laboratories
Glance View

Market Cap
196.2B USD
Industry
Health Care
Economic Moat
Narrow

Nestled into the landscape of global healthcare, Abbott Laboratories emerges as a stalwart that champions scientific innovation and broad accessibility. Established in 1888 by Dr. Wallace Calvin Abbott, the company evolved from a modest medicinal compounding business into a diversified healthcare conglomerate. Today, Abbott's reach extends across more than 160 countries, where it dedicates itself to advancing human health through a wide array of products, including diagnostics, medical devices, nutritionals, and branded generic medicines. This diverse portfolio enables Abbott to remain resilient amid varying market conditions, ensuring its stability and growth are less susceptible to the cyclical nature of any single healthcare segment. Central to Abbott's operations is its prowess in diagnostics and medical devices, both sectors contributing significantly to the company's bottom line. Diagnostics equip healthcare providers with advanced tools to detect diseases early, tailoring treatments to improve patient outcomes—a demand ballooning in tandem with global health awareness. Moreover, Abbott’s innovative medical devices, from cardiovascular to neuromodulation technologies, address some of the most pressing health challenges. Meanwhile, the company’s nutrition products, such as infant formulas and dietary supplements, tap into a burgeoning global appetite for health-conscious living. Each of these ventures feeds into Abbott's strategy of sustaining growth through constant innovation, strategic international expansion, and responsiveness to healthcare trends and needs worldwide. It's this blend of diversification and specialization that keeps the company at the forefront of the healthcare arena.

ABT Intrinsic Value
102.18 USD
Overvaluation 10%
Intrinsic Value
Price

See Also

What is Abbott Laboratories's Cash Equivalents?
Cash Equivalents
7.6B USD

Based on the financial report for Sep 30, 2024, Abbott Laboratories's Cash Equivalents amounts to 7.6B USD.

What is Abbott Laboratories's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
8%

Over the last year, the Cash Equivalents growth was 13%. The average annual Cash Equivalents growth rates for Abbott Laboratories have been -7% over the past three years , 13% over the past five years , and 8% over the past ten years .

Back to Top